Navigation Links
Gene therapy may aid failing hearts
Date:3/26/2013

In an animal study, researchers at the University of Washington show that it was possible to use gene therapy to boost heart muscle function. The finding suggests that it might be possible to use this approach to treat patients whose hearts have been weakened by heart attacks and other heart conditions.

Led by University of Washington (UW) Professor and Vice Chair of Bioengineering Michael Regnier and Dr. Chuck Murry, director of the Center for Cardiovascular Biology and co-director of the Institute for Stem Cell and Regenerative Medicine at UW, the study appears online today in the journal Proceedings of the National Academy of Sciences (PNAS).

Normally, muscle contraction is powered by a molecule, the nucleotide called Adenosine-5'-triphosphate (ATP). Other naturally occurring nucleotides can also power muscle contraction, but, in most cases, they have proven to be less effective than ATP.

In an earlier study of isolated muscle, however, Regnier, Murry and colleagues had found that one naturally occurring molecule, called 2 deoxy-ATP (dATP), was actually more effective than ATP in powering muscle contraction, increasing both the speed and force of the contraction, at least over the short-term.

In the new PNAS study, the researchers wanted to see whether this effect could be sustained. To do this, they used genetic engineering to create a strain of mice whose cells produced higher-than-normal levels of an enzyme called Ribonucleotide Reductase, which converts the precursor of ATP, adenosine-5'-diphosphate or ADP, to dADP, which, in turn, is rapidly converted to dATP.

"This fundamental discovery, that dATP can act as a 'super-fuel' for the contractile machinery of the heart, or myofilaments, opens up the possibility to treat a variety of heart failure conditions," Regnier said. "An exciting aspect of this study and our ongoing work is that a relatively small increase in dATP in the heart cells has a big effect on heart performance."

The researchers found that increased production of the enzyme Ribonucleotide Reductase increased the concentration of dATP within heart cells approximately tenfold, and even though this level was still less than one to two percent of the cell's total pool of ATP, the increase led to a sustained improvement in heart muscle function, with the genetically engineered hearts contracting more quickly and with greater force.

"It looks as though we may have stumbled on an important pathway that nature uses to regulate heart contractility," Murry added. "The same pathway that heart cells use to make the building blocks for DNA during embryonic growth makes dATP to supercharge contraction when the adult heart is mechanically stressed."

Importantly, the elevated dATP effect was achieved without imposing additional metabolic demands on the cells, suggesting the modification would not harm the cell's functioning over the long-term.

The finding, the authors write, suggest that treatments that elevate dATP levels in heart cells may prove to be an effective treatment for heart failure.


'/>"/>

Contact: Clare LaFond
clareh@uw.edu
206-685-1323
University of Washington - Health Sciences/UW News, Community Relations & Marketing
Source:Eurekalert

Related biology technology :

1. Gene Therapy - Technologies, Markets and Companies
2. Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
3. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. Squamous Cell Cancer Responds to SPDT Therapy
6. Stem cell therapy reverses diabetes
7. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
8. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Aethlon Medical, ... results of a study that validated the ability of ... are associated with increased mortality in immune-suppressed sepsis patients ... The objective of the study was ... Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... announced the addition of Tom Perkins as European director. Operating from Pennside’s Zurich ... to Pennside. , Perkins joins Pennside after more than a decade with ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
Breaking Biology Technology:
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/16/2017)... FRANCISCO , Feb. 16, 2017  Genos, ... today announced that it has received Laboratory Accreditation ... CAP Accreditation is presented to laboratories that meet ... who demonstrate scientifically rigorous processes. "Genos ... excellence in laboratory practices. We,re honored to be ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):